The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...

Each of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient's continued service with the Company through the ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Investing in dividend aristocrats can form the cornerstone of a reliable investment strategy, owing to their qualities like ...

Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which faces increasing biosimilar competition from its top-selling rheumatoid arthritis drug Remicade. Estimates from ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Trusted resource of information on Anxiety & Depression that includes articles, news, videos, animations, quizzes, ...

Esketamine, an anaesthetic derived from Ketamine, was approved for use in treating patients with Major Depressive Disorder (MDD) by the Health Sciences Authority (HSA) back in Oct. 2020.